FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib in BRAF+ Advanced Melanoma

On July 31, 2020, Roche announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) plus Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients.

Read corporate press release.

Read FDA announcement.

Posted 7/31/2020